
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is well-positioned in the lucrative anti-VEGF market with their promising treatment option, TH103, and potential for a differentiated and safer profile than their main competitor. Ongoing studies and a new manufacturing batch are expected to support the continued success of TH103, but potential delays in development and approval must also be considered in the overall outlook. As a clinical-stage biopharmaceutical company, Kalaris' strong financials and ability to secure funding demonstrate their dedication to bringing TH103 to market, making it a strong investment opportunity with the potential for long-term growth.
Bears say
Kalaris Therapeutics is a company with a promising new treatment for wet AMD, showing better results than current standard of care, and a strong financial position. However, potential risks in regulatory and commercial aspects, along with the need for effective marketing, could impact the success of their pipeline and their ability to reach the current price target of $19. As a result, it is important to closely monitor their progress and the potential challenges they may face.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares